ABSTRACT
INTRODUCTION
Awareness on the role of kidney in glucose homeostasis has led to the development of a new Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 51E4F0605031B5AE. pharmacological class of anti-hyperglycemic agents. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a novel and growing class of anti-diabetic drugs that lower blood glucose levels through the inhibition of renal glucose reabsorption thereby enhancing renal glucose excretion [1] [2] [3] . This approach of glucose-lowering is independent of insulin action or beta-cell function and complementary to other anti-diabetic drugs [4] . Treatment with SGLT2i has demonstrated improvements in glycosylated hemoglobin (HbA1c), reduction in body weight and modest lowering of blood pressure (BP) [2, 5] . The pharmacological inhibition of renal glucose reabsorption through selective inhibition of SGLT2 has thus opened a new arena in the treatment of diabetes mellitus (DM).
The ability of SGLT2i to reduce the plasma glucose levels is directly proportional to the glomerular filtration rate (GFR) [6] , and hence, is expected to be decreased in chronic kidney disease (CKD). On the other hand, ongoing research suggests that SGLT2i may offer potential nephroprotection in diabetes [7] [8] [9] .
The
SGLT2i could reduce glomerular hyperfiltration, systemic and intraglomerular pressure and accordingly, the progression of CKD, even in those without DM [10] . The efficacy of SGLT2i decreases with renal impairment while on the other hand, SGLT2i protect against the renal injury. Thus, the SGLT2i and glomerulus both impact each other and possess a bidirectional relation. Exploring this bidirectional relationship of the SGLT2i and the glomerulus in healthy individuals, patients with diabetes, and in different degrees of kidney disease is of particular importance to understand their therapeutic potential in these conditions. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
ROLE OF KIDNEYS IN GLUCOSE METABOLISM
The kidneys play a major role in the regulation of glucose reabsorption and in maintaining the overall metabolic balance in humans [6] . More than 99% of the plasma glucose that filters through the renal glomeruli is reabsorbed [11] .
The transport of glucose across cell membranes is mediated primarily by two different types of sodium-glucose cotransporters: SGLT1 and SGLT2.
The SGLT2, a high-capacity, low-affinity glucose transporter is located primarily in the brush border membrane of the S1 segment of the proximal renal tubule and is responsible for reabsorption of more than 90% of filtered glucose in the kidney [12] . The SGLT1, a high-affinity, low-capacity glucose transporter, reabsorbs the remaining 10% of filtered glucose and is primarily expressed in the gastrointestinal tract ( Fig. 1 ) [13] .
Glucose Reabsorption in Healthy Kidney
Kidneys achieve glucose homeostasis via three pathways: uptake of glucose from the circulation, renal gluconeogenesis and glucose reabsorption from the glomerular filtrate [6] . In a healthy individual, about 180 g of glucose is filtered from plasma by glomeruli every day. However, under normal circumstances, the filtered glucose is almost completely reabsorbed in the proximal tubules by the SGLT2 and SGLT1, leaving minimal or no glucose in the urine [6] . This state of no or minimal glucosuria is maintained in the healthy individuals (Fig. 1 ).
This ability of proximal tubules to reabsorb almost all the filtered glucose, via SGLTs, healthy adults. Above this concentration, the excess glucose cannot be reabsorbed and is excreted resulting in glucosuria [6, 14] .
Glucose Reabsorption in Diabetic Kidney
In patients with diabetes, the blood glucose levels increase and exceed the Tm glucose at a threshold of approximately 200 mg/dL.
Consequently, the excess glucose is not reabsorbed leading to glucosuria. However, in diabetes, expression of the SGLT2 transporter genes is up-regulated and the renal threshold is increased [6, 15] . This results in increased glucose reabsorption from glomerular filtrate in patients with diabetes reducing urinary Fig. 1 Glucose reabsorption pathway and SGLT2 inhibition. T2DM type 2 diabetes mellitus, SGLT sodium-glucose cotransporter glucose excretion (UGE) and further worsening the hyperglycemic condition [6, 15] . Hence, suppressing the glucose reabsorption and increasing the glucosuria through inhibition of the SGLT2 is considered as an effective and practical approach for the correction of this intensified hyperglycemia.
EFFECTS OF SGLT2 INHIBITORS

In Healthy Individuals
Clinical studies have revealed that treatment with SGLT2i reduces renal threshold for glucose excretion and increases UGE in healthy individuals, dose-dependently [3, 16, 17] . Existing evidence suggests that treatment with SGLT2i in healthy individuals leads to continuous glucose excretion in urine with a corresponding loss in calories [3, 16, 17] .
However, this increase in glucose excretion does not alter the plasma glucose levels in healthy individuals since liver compensates the loss of glucose with increased glucose production to avoid hypoglycemia. This raises the possibility of SGLT2i being used for weight reduction among healthy individuals.
Empagliflozin has demonstrated significantly increased glucose excretion in urine as well as weight loss without any changes in body water or protein content in diet-induced obese rats for 4 weeks [18] . However, evidence confirming the role of SGLT2i as an option for weight reduction treatment in healthy humans is limited. In a recent 12-week, placebo-controlled, dose-ranging study, canagliflozin (50, 100, or 300 mg/day) reduced body weight by 1-2%, as compared with placebo. Though the drug was generally well-tolerated in overweight and obese participants without DM, the magnitude of weight reduction did not support the use of SGLT2 inhibition monotherapy as a viable weight loss intervention [19] .
In Patients with Diabetes
SGLT2i inhibit renal glucose reabsorption by inhibiting SGLT2 in the kidney, which in turn facilitates the renal glucose excretion (Fig. 1) .
As the UGE increases, the plasma glucose levels fall leading to the improvement in all glycemic parameters [1] [2] [3] . Selective SGLT2i exhibit minimal or no risk of hypoglycemia as their action diminishes when the plasma glucose concentrations decrease [20] . The SGLT2i are generally well-tolerated with common adverse events of urinary and genital infections [21] .
An added advantage is that SGLT2i can be administered as an add-on therapy along with the existing anti-diabetic agents because of their insulin-independent mechanism of action. Table 1 .
Mild Renal Impairment
Evidences suggest that the glucose-lowering efficacy and safety of SGLT2i in patients with mild renal impairment was comparable to those observed in patients with normal kidney function [32, 34] . This implies that SGLT2i may be used in patients with mild renal impairment without dose-adjustments.
Moderate Renal Impairment
The ability of SGLT2i to promote UGE reduces with decreasing GFR, and hence, patients with 
Severe Renal Impairment
As the pharmacodynamic effect of SGLT2i is primarily dependent on GFR, no glycemic therapeutic benefits are anticipated in patients with severe renal impairment or renal failure. Evidence suggests little or no effect of SGLT2i on the UGE in patients with severe renal impairment or renal failure; hence, its use is contraindicated in this population [32, 33, 35] .
PATHOGENESIS OF DIABETIC NEPHROPATHY
Of the known complications of diabetes, diabetic nephropathy (DN) is of particular concern as it is a leading cause of CKD, worldwide [8, 9, 37] . DN is characterized by a progressive increase in proteinuria and decline in GFR, associated with hypertension, finally culminating in end-stage renal disease (ESRD) [38, 39] . Recent research has been focused on understanding the pathogenic mechanisms that initiate the progression of early DN towards ESRD.
Glomerular Hyperfiltration
Glomerular hyperfiltration is an early renal hemodynamic abnormality in patients with diabetes and has been identified as a surrogate marker of increased intraglomerular pressure The pathogenesis of glomerular hyperfiltration is not completely understood; however, both hemodynamic and tubular mechanisms have been associated with this condition (Fig. 2 ).
Hemodynamic Hypothesis
The hemodynamic hypothesis is based on the Approved doses: Canagliflozin-The recommended dose is 100 mg or 300 mg/day. The 300 mg dose may be considered for patients tolerating 100 mg/day who have an estimated GFR of 60 mL/min/1.73 m 2 or greater and require additional glycemic control Dapagliflozin-recommended starting dose is 5 mg, can be increased to 10 mg/day in patients tolerating 5 mg/day who require additional glycemic control Empagliflozin-recommended starting dose is 10 mg, can be increased to 25 mg/day H = Can be used, X = cannot be used CKD chronic kidney disease, GFR glomerular filtration rate a Limited to 100 mg/day progression of disease in diabetic patients [45] [46] [47] [48] . Even the dual RAAS blockage mechanism involving both ACE inhibition and renin inhibition was not able to fully attenuate hyperfiltration [7] . Hence, as the nephroprotective effects of RAAS blockage therapies are limited, there is a crucial need for alternative therapies for renal protection in patients with diabetes [7] .
Tubular Hypothesis
The tubular hypothesis is based on the increase in sodium reabsorption at the proximal tubule mediated by SGLT2. In diabetes, hyperglycemia leads to filtered glucose load coupled with increased expression of SGLT2. As a result, more glucose and sodium is reabsorbed in the proximal tubules leading to reduced delivery of sodium to the macula densa. This condition is sensed by the macula densa as a reduction in effective circulating volume causing reduction in adenosine generation in the juxtaglomerular apparatus. This causes afferent renal vasodilation leading to hyperfiltration (Fig. 3) [10]. The need for alternative non-RAAS dependent therapies for DN has highlighted the importance of therapies targeting tubular hypothesis.
Hypertension
In T2DM, hypertension commonly precedes kidney disease [39] . Several studies have 
EFFECT OF SGLT2 INHIBITORS ON RENAL FUNCTION
The mechanism of action of SGLT2i depends on filtration of glucose at the glomerulus.
Therefore, these drugs are less effective in patients with renal impairment. However, evidence suggests that SGLT2i may possess nephroprotective effect in DN. The SGLT2i have been shown to reduce glomerular hyperfiltration, systemic and intraglomerular pressure, and accordingly, the progression of CKD [8, 52] .
The rationale for using SGLT2i as a nephroprotective therapy is compelling as SGLT2i has the potential to modify the Table 2 .
Experimental studies have suggested that SGLT2i ameliorate glomerular hyperfiltration reduce albuminuria, kidney hypertrophy and inflammation in animal models of T1DM and T2DM [8, 10, 53] . Treatment with SGLT2i has shown to reduce intrarenal inflammation in diabetic db/db mice [52] . In this study, decreased macrophage infiltration, inflammatory response and oxidative stress in the kidney were noted with dapagliflozin treatment. These effects were found to be independent of it's glucose-lowering effects.
Conversely, a recent study in T1DM endothelial nitric oxide synthase knockout mice, showed no renoprotective benefits of empagliflozin apart from glucose-lowering effects [54] . Preclinical data on nephroprotective role of ClinicalTrials.gov identifier: NCT02065791) study, is in progress [55] .
Besides having anti-hyperglycemic activity, SGLT2i induce weight loss, osmotic diuresis and BP-lowering. Although not approved for BP-lowering, they can potentially help achieve target BP in patients with diabetes who require BP reduction of 7-10 mmHg [56, 57] . While the exact mechanism of BP-lowering effect with SGLT2i is not yet fully established, the osmotic diuretic effect of these agents has been related HbA1c glycosylated hemoglobin, Na sodium, SGLT2 sodium-glucose cotransporter-2 most often to BP reduction [56] . A randomized, placebo-controlled study in patients with T2DM
(n = 75) showed reductions in 24-h systolic BP (-3.3 mmHg) with dapagliflozin treatment (10 mg/day) compared with -0.9 mmHg for placebo [58] . SGLT2i reduces albuminuria, which is a predominant renal risk marker in DN [59] . reductions of approximately 35% with dapagliflozin 10 mg/day, relative to placebo. In addition, these reductions were shown to be independent of changes in HbA1c, systolic BP, body weight or eGFR [60] .
Serum uric acid-lowering is another mechanism by which SGLT2i may exert their nephroprotective effect. Elevated levels of uric acid, also known as hyperuricemia, have been shown to highly correlate with the risk of renal damage in diabetes [62] [63] [64] , and are responsible for microvascular disease in diabetes [65, 66] .
Animal studies have revealed that uric acid may induce tubular damage in DN [67] . Given the various metabolic effects of hyperuricemia in patients with diabetes, the uric acid-lowering effect of SGLT2i may be clinically important and is evidenced in several studies [27, 68, 
ADVANCED GLYCATION END PRODUCTS
Advanced glycation end products (AGEs) are the covalent adducts of glucose with the plasma proteins, formed during chronic hyperglycemia. 
SGLT2 INHIBITORS VERSUS RAAS-BASED AGENTS IN DIABETES THERAPY
SGLT2i and the RAAS-based agents like ACEi or ARBs clearly have different mechanisms of action and different effects on the renal system (Table 3 ; was associated with additive nephroprotective effect in DN compared to either drug alone [76] .
The EMPA-REG OUTCOME study (ClinicalTrials.gov identifier: NCT01131676), assessing the long-term cardiovascular safety of empagliflozin in 7034 patients with T2DM and high cardiovascular risk, had 80% of the patients on RAAS blockers at baseline for BP reduction [77] . In addition, 26% of the patients had moderate renal impairment. Treatment with empagliflozin was associated with substantial improvement in all the renal function parameters. The nephroprotective effect of SGLT2i could also contribute to cardiovascular benefits by inducing volume depletion and neurohormonal activation [78] .
SAFETY OF SGLT2 INHIBITORS
Although owing to their mechanism of action, SGLT2i are associated with low risk of hypoglycemia, they may lead to adverse effects like genital mycotic and urinary tract infections [21] . This may be attributed to the increased and prolonged glucosuria induced by SGLT2i. Although these side effects are not of serious nature, patients and the 
Inflammatory cell infiltration Ameliorated
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, HbA1c glycosylated hemoglobin, Na sodium, NADPH nicotinamide adenine dinucleotide phosphate, RAAS renin-angiotensin-aldosterone system, SGLT2 sodium-glucose cotransporter-2 health care providers should be aware of them.
Another reported adverse effect of SGLT2i treatment is osmotic diuresis which results in dehydration, hypotension and renal impairment. Intravascular volume depletion was also observed with SGLT2i therapy [79] . In diabetic patients with renal impairment, a dose-dependent increase in serum creatinine, a known marker of renal damage, was observed [4] . A recent case report suggested the association of SGLT2i treatment with renal tubule dysfunction or Fanconi syndrome. However, it must be noted that this was observed in a T1DM patient, in whom canagliflozin was used off-label. Such potential adverse effects should be confirmed with further studies [80] . Hence, despite their proven nephroprotective role, SGLT2i should be prescribed with caution in patients with diabetes with significant renal impairment.
CONCLUSIONS
The SGLT2i with their novel insulin-independent glucose-lowering action and associated benefits on body weight and BP, are proving to be promising options either as monotherapy or as an add-on therapy for patients with diabetes not controlled with existing medications. Owing to their kidney-dependent mechanism of action, the glucose-lowering ability of SGLT2i decreases with an increase in severity of glomerular dysfunction in patients with DN. However, they have been proven to be useful at all stages of kidney disease except for the severe renal impairment or renal failure where they provide no therapeutic benefits. Additionally, in light of the recent research demonstrating the nephroprotective role of SGLT2i, they may prove to be beneficial for patients with DN. 
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